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Purpose: The purpose of this study was to test the efficacy of arginine, alanine, and phenylala-
nine mixture (A-mix) ingestion at 1,500 mg/day in combination with the promotion of physical 
activity for abdominal fat reduction in overweight adults.
Methods: A placebo-controlled, double-blind, parallel-group, randomized trial for 12 weeks 
combined with a 4-week follow-up period was conducted at a single center in Minato-ku, 
Tokyo, Japan, between December 2016 and May 2017. Data were analyzed between June and 
August 2017. The study participants were 200 overweight adults within the age range of 20–64 
years. The participants were randomly assigned to the A-mix group (n=100) or a placebo group 
(n=100) and were administered 500 mL of test beverage containing 1,500 or 0 mg of A-mix, 
respectively, for 12 weeks. All participants maintained a physically active lifestyle between week 
0 and week 12 through monthly sessions of physical activity. The primary outcomes were the 
12-week changes in the abdominal total, subcutaneous, and visceral fat areas, as assessed by 
computed tomography.
Results: Of the 200 enrolled participants, 199 (99%) accomplished the 12-week intervention 
and 4-week follow-up period. The per-protocol-based analysis for 194 participants demonstrated 
that the abdominal total fat area decreased significantly in the A-mix group compared with that in 
the placebo group (difference, 10.0 cm2; 95% confidence interval [CI]: 0.4–19.6 cm2; P=0.041). 
Comparable outcomes were obtained for the abdominal subcutaneous fat area (difference, 7.4 
cm2; 95% CI: 0.1–14.7 cm2; P=0.047). No study-related unfavorable events occurred.
Conclusion: A-mix supplementation in combination with physical activity promotion facilitated 
abdominal fat reduction in overweight adults.
Keywords: amino acid supplementation, physical activity promotion, abdominal fat, random-
ized controlled trial
Introduction
Obesity, which is a common medical issue worldwide,1 is a major risk factor for type 2 
diabetes, insulin resistance, atherosclerosis, hypertension, stroke, and several types of 
cancer.2 The condition results from a chronic imbalance in energy metabolism. To avoid 
or alleviate the risks associated with obesity, weight reduction by dietary restriction 
and a general exercise program is viewed as the best, accessible, nonpharmacologic, 
and nonsurgical treatment system.3
The additive effects or synergistic impact of eating routines and exercise have 
recently been thoroughly studied.4,5 Our research group has considered the impact of 
amino acid supplementation, in combination with exercise, on fat oxidation for over 
two decades.6–15 Recently, we concentrated on the amino acids arginine, alanine, and 
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phenylalanine, which are involved in glucagon synthesis 
and secretion when delivered acutely. We also established 
that a single session of aerobic exercise in conjunction with 
oral administration of a mixture of arginine, alanine, and 
phenylalanine (A-mix) increased blood ketone body levels 
compared with placebo in humans.13,14 These conclusions 
indicated a lipolytic effect during exercise that was likely 
a result of A-mix ingestion. Moreover, we recently con-
ducted a pilot randomized controlled trial to evaluate the 
long-term efficacy of A-mix consumption in conjunction 
with physical activity promotion for overweight individu-
als, and this trial helped to estimate the effective dose of 
the mixture. The pilot trial suggested that a dose of 1,500 
mg/day of A-mix facilitated abdominal fat reduction in 
overweight adults.16
Therefore, we conducted a randomized controlled trial 
to confirm the efficacy of the combination of 1,500 mg/
day A-mix ingestion with physical activity promotion in 
abdominal fat reduction in overweight adults between the 
age of 20 and 64 years.
Methods
Trial design
The study had a double-blind, placebo-controlled, parallel-
group, and randomized design. The trial was a single-center 
study organized at a site in Minato-ku, Tokyo, Japan, and 
was conducted between December 2016 and May 2017. 
The data were analyzed between June and August 2017. 
The target number of participants was set at 200 (i.e., 100 
participants per group), as a sample size of 100 participants 
in each group enabled us to perceive a group difference 
effect size (Cohen’s d) of 0.4 with a significance level of 
5% and a power of 80%. Given the assumption that some 
individuals would refuse to participate in the trial or fail to 
meet the inclusion criteria, a target number of 340 adults 
was set for the introductory session. The investigation pro-
tocol was approved by the  Institutional Review Board of 
the University of Tsukuba Faculty of Medicine, the Meiji 
Institutional Review Board, and the Ethical Committee of 
Nihonbashi Cardiology Clinic. Written informed consent 
was obtained from each participant before randomization. 
The study protocol was enrolled in the UMIN Clinical Trials 
Registry (UMIN000025186) on December 10, 2016. This 
article completely conforms to the Consolidated Standards 
of Reporting Trials 2010 rules.17 A data monitoring group 
guaranteed the  accuracy of information collected and the 
sources of information.
Participants
Participants were recruited from a volunteer database asso-
ciated with a contract research organization. The included 
participants had to be overweight (25 kg/m2≤body mass 
index [BMI]<30 kg/m2) adults between 20 and 64 years of 
age. Individuals were excluded if they 1) continually used 
oral medication that might conceivably influence the body 
weight and lipid metabolism; 2) had food allergies or cardio-
vascular, severe hepatic, respiratory, metabolic, or endocrine 
disorders; 3) could not avoid the use of health food products 
or supplements that might conceivably influence the body 
weight and lipid metabolism; 4) had a current or previous 
history of drug or alcohol dependence; 5) could not abstain 
from alcohol consumption for 2 days before each measure-
ment visit; 6) had metal installed in their abdominal site; 7) 
had a cardiac pacemaker or an implanted defibrillator; 8) were 
diagnosed with hyperphenylalaninemia or phenylketonuria; 
9) had a history of familial hyperlipidemia; 10) were currently 
pregnant, nursing, or intended to become pregnant during the 
study period; 11) had extremely irregular dietary propensities 
or lifecycle, for example, midnight working; 12) participated 
or were eager to participate in clinical trials of other foods, 
medications, or beauty products; 13) had a fear of confined 
places; and 14) were judged as inappropriate for the study by 
the principal investigator owing to abnormal blood or urine 
parameters, or other reasons.
Randomization and blinding
After arrangement by sex and intervention waves, the par-
ticipants who met the inclusion criteria were randomized 
to the A-mix or placebo group with a 1:1 allocation ratio. 
An investigator who had no contact with the participants 
and staff individuals created a random number sequence by 
using an approved computer program. The random sequence 
was kept by an assigned individual who was accountable for 
shipping the test beverages to the participants but was not 
involved in the plan, enrollment, evaluation, intervention, or 
analysis. The participants, investigators, and all staff members 
involved in the trial were blinded to the group allocation. The 
randomization code was opened after the study information 
was checked, collated, and finalized.
Interventions
Test beverage
The test preparation for the A-mix and placebo groups con-
sisted of a 500 mL polyethylene terephthalate bottle beverage 
that contained 1,500 and 0 mg of A-mix, respectively. The 
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test beverages had an identical appearance and comparable 
tangible attributes. The ingredients of the A-mix were as 
follows: 42% mol/mol of phenylalanine, 38% mol/mol of 
alanine, and 20% mol/mol of arginine. Each bottle of the 
test beverage contained 20 and 13 kcal for the A-mix and the 
placebo groups, respectively. Neither of the test beverages 
contained caffeine. The assigned individual transported the 
test beverages to the participants based on group allocation. 
The participants were instructed to keep the test beverages 
away from high humidity, high temperature, and direct sun-
light and to consume one bottle per day before and during 
physical activity or exercise under free-living conditions.
Physical activity promotion
Regardless of group allocation, the participants followed a 
monthly physical activity promotion session throughout the 
12-week intervention period (four sessions in total). The 
intervention program consisted of a group-based exercise 
class with personalized advice. Participants were urged to add 
1,000 steps/day or more from their benchmark step targets 
suggested by the current Japanese physical activity recom-
mendations.18,19 The group-based exercise class started with 
a 30 min lecture and a 60 min group-based workout session 
that included walking, muscle strengthening, and stretching. 
Trained professionals conducted the personalized advice ses-
sions in conjunction with the analysis of participants’ recent 
step counts, body weight, test beverage ingestion, physical 
condition, medication use, dietary behaviors, daily step 
counts measured by pedometer (FB-736; Tanita Corporation, 
Tokyo, Japan), and exercise, all of which were recorded in 
diaries. To avoid the confounding effects of lifestyle changes, 
participants were instructed to consume well-balanced meals 
three times per day in accordance with the Japanese Food 
Guide Spinning Top20 and to abstain from excessive strenuous 
exercise, gorging, serious activity restrictions, ingestion of 
healthful supplements, functional foods, and over-the-counter 
medications that could possibly influence the results.
Measurements
All study outcomes, except for abdominal fat area, were 
assessed at baseline and at each visit after 4 weeks by 
experienced staff members who were blinded to the group 
allocation. The abdominal fat areas were scanned by using 
computed tomography (CT) at the baseline and 12-week 
visits. The primary outcome measures were the 12-week 
changes in the abdominal fat areas. The secondary outcomes 
comprised changes in body weight, percent fat mass, waist 
and hip circumferences, and metabolic risk factors such as 
lipid profiles, blood glucose parameters, and blood pressure. 
To monitor adherence to the intervention, dietary intake was 
measured every 4 weeks and physical activity was measured 
at baseline and week 12.
Anthropometrics and body composition
Body weight (to the nearest 0.1 kg) and percent fat mass (to 
the nearest 0.1%) were measured by using a multi-frequency 
bioelectrical impedance device (InBody 430; Biospace, 
Seoul, Korea).21 Height was measured to the nearest 0.1 cm 
by utilizing a compact stadiometer (DSN-90; Muratec-KDS 
Corp., Kyoto, Japan) at baseline. BMI was estimated from 
participants’ weight in kilograms divided by their height in 
meters squared. Waist and hip circumference were measured 
twice to the nearest 0.1 cm at the umbilicus and maximum 
circumference of buttocks, respectively in the standing posi-
tion by using a flexible plastic tape. The average value of the 
two measurements was used for analysis. Waist to hip ratio 
was calculated from participants’ waist circumference divided 
by their hip circumference. 
Abdominal fat areas
The abdominal fat areas were analyzed at the L4 level by 
using CT (Supria; Hitachi Ltd, Tokyo, Japan) and computed 
by a commercial program (Fat Scan Ver. 5.0.; e-JAPAN IT 
Co., Ltd, Ibaraki, Japan).22
Blood pressure readings
Systolic and diastolic blood pressure readings were measured 
with a mechanized sphygmomanometer (Digital Automatic 
Blood Pressure Monitor HEM-907; Omron Healthcare, 
Kyoto, Japan). The measurements were taken on the arm 
of seated participants who had rested for no less than 5 min 
with the arm supported at the heart level. An average value 
of both readings was used for data analysis.
Blood biochemistry
A blood sample was drawn from each participant after an 
overnight (≥12 h) fast. Venous blood was assayed by an 
independent laboratory (LSI Medience Corporation, Tokyo, 
Japan). The levels of serum total cholesterol (IatoroLQ 
T-CHO(A) II; LSI Medience Corporation) and triglycer-
ides (IatoroLQ TG II; LSI Medience Corporation) were 
determined enzymatically. Serum high- and low-density 
lipoprotein cholesterol levels were measured by the selec-
tive inhibition method (MetaboLead HDL-C and Metabo-
Lead LDL-C, respectively; Kyowa Medex Co., Ltd, Tokyo, 
Japan). Blood glucose was assayed by an enzymatic method 
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(IatoroLQ GLU; Unitika, Aichi, Japan) and insulin by a 
chemiluminescent immunoassay (Architect Insulin; Abbott 
Japan, Tokyo, Japan). Glycated hemoglobin A (HbA
1c
) was 
determined enzymatically (CinQ HbA1c; ARKRAY Inc., 
Kyoto, Japan). Homeostasis model assessment of insulin 
resistance (HOMA-R) was calculated using the following 
formula: Blood glucose (mg/dL) × insulin (μU/mL) / 405.
Dietary intake
The macronutrient intake in grams and the total energy intake 
in kilocalories were evaluated from records of food intake 
over 3 days. Participants were instructed to record their total 
food consumption for 3 days, including two weekdays and 
one weekend day. Food quantities were measured by using 
standard measuring glasses, spoons, and digital scales.
Physical activity
Physical activity was measured by using a triaxial accelerom-
eter (Active style Pro HJA-750C; Omron Healthcare) worn 
at the waist for 7 days. The accelerometer counted steps and 
computed the intensity of physical activity (expressed as meta-
bolic equivalents) from a published algorithm.23,24 The devices 
were not worn during sleeping, water-based activities (e.g., 
washing or swimming), or participating in certain exercises 
for safety reasons (e.g., contact sports). Records obtained were 
characterized as substantial when a device was worn for no 
less than 10 h/day.25 When substantial records were gathered 
for over 1 day, step counts and time spent in moderate to 
vigorous physical activity (≥3 metabolic equivalents) were 
calculated for each participant.
Safety assessment
Hematology tests, blood biochemical tests, and urinalyses 
were performed at every visit after 4 weeks. At the same 
visit, a medical staff checked the health status of the par-
ticipants by means of a medical interview and consultation 
with their diaries.
Adverse events
Data on adverse events were subjectively obtained through 
the participants’ diaries and were independently analyzed by 
using pulse rate measurements and blood hematologic and 
biochemical tests. In this trial, an adverse event was charac-
terized as any negative and unintended sign, manifestation, 
Figure 1 Flowchart of trial participants.
Abbreviations: BMI, body mass index; PPB, per-protocol-based.
Invited to introductory session (n=377)
Agreed to participate (n=370)
Assessed for eligibility (n=340)
Randomized (n=200)
Excluded (n=140)
-BMI < 25 or 30 ≤ (n=43) 
-Withdrew consent (n=18) 
-Abnormal  blood and urine
 parameters or other reasons (n=79)
A-mix group (n=100) Placebo group (n=100)
Completed the entire study (n=99)
-Relocation (n=1)
Completed the entire study (n=100)
Included in the PPB analysis set (n=95)
    -Missed 12-week follow-up visit (n=1)
    -Ineligible after randomization (n=1)
    -Violation of study compliance (n=2)
Included in the PPB analysis set (n=99)
    -Violation of study compliance (n=1)
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or malady. The study physician then judged whether a given 
unfavorable event was serious or nonserious, and if it was 
study related. 
Statistical analysis
All statistical analyses were performed in accordance with 
the analysis plan in the study protocol using IBM SPSS 
Statistics Ver. 24 (IBM Japan, Ltd, Tokyo, Japan). Values of 
P<0.05 were considered statistically significant. The baseline 
participant characteristics were presented as the mean and 
standard deviation for continuous variables or as frequen-
cies and percentages for categorical variables. Our primary 
analysis followed a per-protocol-based (PPB) principle, in 
which we excluded participants who met no less than one 
of the accompanying predetermined criteria as follows: 1) 
missed the 12-week visit; 2) low compliance rate (<80%) for 
consumption of the test beverages; 3) absent or inadequate 
diary logs; 4) announced ineligible after randomization; and 
5) serious infringement of study consistence, as judged by 
the principal investigator.
An unpaired Student’s t-test was used to compare the 
12-week changes in the primary, secondary, and compliance 
outcomes. A stratified analysis was conducted: those with 
step counts increased by 1,000 steps or more and those with 
step counts increased by fewer than 1,000 steps during the 
12-week intervention period. In the safety assessment, the 
adverse events and deviations identified by fasting blood 
tests were compared between the two groups by using chi-
square tests for categorical variables and unpaired t-tests for 
 continuous variables. In addition, paired t-tests were used 
to compare the data before and after the intervention within 
each group.
Results
The complete flow chart of the study participants is displayed 
in Figure 1. A total of 377 candidates attended the introduc-
tory session; written informed consent was obtained from 370 
participants and the baseline examination was completed by 
340 participants. Finally, 200 individuals met the inclusion 
criteria and were assigned randomly to the A-mix group 
(n=100) or to the placebo group (n=100).
The characteristics of the participants measured at 
baseline are presented in Table 1. There were no significant 
differences in any study or compliance outcomes between 
the two groups. Among the 200 participants, 199 (99%) 
completed the 12-week intervention and 4-week follow-up 
period; of the 199 who completed the trial, the median rate 
of test beverage intake was 100% with no between-group 
difference (P=0.42; Mann–Whitney U test). After the exclu-
sion of five additional participants (1 missed the 12-week 
visit, 1 was ineligible after randomization, and 3 seriously 
violated the study compliance requirements), 194 participants 
were included in the PPB analysis.
The results of the PPB analyses of the primary and 
secondary outcomes are presented in Table 2 and Figure 
2, and those of the compliance outcomes are summarized 
in Table 3. The abdominal total fat area decreased signifi-
cantly in the A-mix group compared with that in the placebo 
group (difference, 10.0 cm2; 95% confidence interval [CI]: 
0.4–19.6 cm2; P=0.041). Similar results were obtained for the 
abdominal subcutaneous fat area measurements (difference, 
7.4 cm2; 95% CI: 0.1–14.7 cm2; P=0.047). No noteworthy 
Table 1 Baseline characteristics of the participants (n=200)
Characteristic A-mix group 
(n=100)
Placebo group  
(n=100)
Female, n (%) 50 (50) 50 (50)
Age, years 43.5 (9.9) 43.5 (9.7)
Height, cm 164.9 (9.2) 164.3 (8.2)
Weight, kg 73.5 (9.1) 73.4 (7.8)
Body mass index, kg/m2 27.0 (1.2) 27.1 (1.3)
Percent fat mass, % 32.1 (6.9) 32.4 (6.9)
Waist circumference, cm 93.8 (5.8) 93.6 (4.9)
Hip circumference, cm 101.2 (4.2) 100.5 (3.8)
Waist to hip ratio 0.93 (0.05) 0.93 (0.05)
Abdominal fat area, cm2
Total 339.2 (73.4) 327.6 (71.1)
Subcutaneous 244.0 (66.2) 229.7 (70.4)
Visceral 95.2 (35.9) 98.0 (38.9)
Blood pressure, mm Hg
Systolic 129.8 (13.6) 129.4 (12.5)
Diastolic 77.6 (10.4) 77.5 (10.6)
Blood biochemical parameters
Triglycerides, mg/dL 103.1 (53.8) 113.4 (55.5)
Total cholesterol, mg/dL 208.3 (33.5) 215.0 (30.2)
HDL-C, mg/dL 58.3 (13.8) 56.4 (11.3)
LDL-C, mg/dL 126.1 (30.6) 133.6 (27.1)
Fasting blood glucose, mg/dL 85.1 (6.2) 85.3 (7.4)
Glycated hemoglobin A1c, % 5.5 (0.3) 5.5 (0.3)
Fasting insulin, mU/mL 5.6 (2.7) 5.8 (2.4)
HOMA-R 1.18 (0.61) 1.22 (0.53)
Dietary intake
Total energy, kcal/day 1,934 (471) 1,850 (393)
Protein, g/day 72.4 (21.0) 68.1 (16.0)
Fat, g/day 67.1 (22.0) 63.0 (17.0)
Carbohydrate, g/day 243.8 (62.0) 238.5 (57.1)
Physical activity
Step counts, steps/day* 7,565 (3,308) 8,454 (3,598)
MVPA, min/day* 65.5 (32.7) 70.2 (37.2)
Notes: Data shown as mean (standard deviation) unless specified. *Data were 
available for 198 participants (100 and 98 in the A-mix and the placebo groups, 
respectively).
Abbreviations: HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density 
lipoprotein cholesterol; HOMA-R, homeostasis model assessment of insulin 
resistance; MVPA, moderate-to-vigorous physical activity.
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by the study physician to be related to the consumption 
of the study beverage. Moreover, a total of 456 deviations 
from the reference ranges were identified through blood 
analysis (Table S2). Although there were significant dif-
ferences between groups, such as increased number of red 
blood cells, elevated levels of hemoglobin, decreased levels 
of aspartate amino transferase, decreased levels of alanine 
aminotransferase, elevated levels of total bilirubin, elevated 
levels of blood urea nitrogen, elevated levels of calcium, 
and elevated levels of serum iron, there were no clinically 
significant variations from the norm or discoveries, as judged 
by the study physician, due to the consumption of the test 
beverage on the basis of the physical assessments, blood 
biochemical analyses, and hematologic parameters. The 
results of the blood analyses and urinalyses are summarized 
in Tables S3–S6.
Discussion
The aim of this study was to test the efficacy of A-mix in 
conjunction with the promotion of physical activity for 
the reduction of abdominal fat in overweight adults. We 
found significantly larger reduction in abdominal total and 
subcutaneous fat areas in the A-mix group compared with 
the placebo group. From a safety perspective, no serious, 
Table 2 Per-protocol-based analyses for primary and secondary outcomes (n=194)
Outcome A-mix group (n=95) Placebo group (n=99) P-value
Week 0 Week 4 Week 8 Week 12 Week 16 12-week change Week 0 Week 4 Week 8 Week 12 Week 16 12-week change
Primary outcomes
Abdominal total fat area, cm2 338.8 (73.6) NA NA 320.5 (76.1) NA
−18.3 (−25.8, −10.8) 326.2 (70.0) NA NA 317.8 (71.3) NA −8.3 (−14.5, −2.2) 0.041
Abdominal subcutaneous fat area, cm2 245.2 (66.1) NA NA 236.3 (68.1) NA
−8.9 (−14.5, −3.3) 228.3 (69.4) NA NA 226.8 (69.1) NA −1.5 (−6.2, 3.3) 0.047
Abdominal visceral fat area, cm2 93.6 (35.6) NA NA 84.1 (34.0) NA
−9.5 (−12.9, −6.0) 97.9 (39.0) NA NA 91.0 (38.8) NA −6.8 (−9.6, −4.1) 0.24
Secondary outcomes
Weight, kg 73.6 (8.9) 73.2 (8.7) 73.0 (8.8) 72.4 (8.7) 72.6 (8.8)
−1.2 (−1.7, −0.8) 73.5 (7.8) 73.1 (8.0) 72.9 (7.9) 72.3 (7.8) 72.4 (7.8) −1.2 (−1.7, −0.8) 0.96
Body mass index, kg/m2 27.1 (1.2) 27.0 (1.2) 26.9 (1.2) 26.7 (1.3) 26.7 (1.3)
−0.4 (−0.6, −0.3) 27.2 (1.3) 27.0 (1.4) 26.9 (1.5) 26.7 (1.5) 26.8 (1.6) −0.5 (−0.6, −0.3) 0.94
Percent fat mass, % 31.9 (7.0) 32.1 (7.4) 32.1 (7.4) 30.7 (7.5) 31.4 (7.7)
−1.2 (−1.6, −0.8) 31.8 (6.8) 32.2 (7.2) 32.0 (7.0) 30.6 (7.1) 31.3 (7.4) −1.2 (−1.6, −0.9) 0.93
Waist circumference, cm 94.0 (5.4) 93.8 (5.4) 93.0 (5.2) 92.6 (5.4) 92.3 (5.7)
−1.4 (−1.9, −0.9) 94.0 (5.4) 93.9 (5.4) 93.4 (5.4) 92.8 (5.5) 92.5 (5.5) −1.2 (−1.8, −0.7) 0.65
Hip circumference, cm 100.8 (4.3) 100.7 (4.0) 100.4 (4.0) 100.0 (4.1) 100.0 (4.2)
−0.8 (−1.2, −0.4) 100.2 (3.6) 100.1 (3.6) 99.8 (3.7) 99.6 (3.7) 99.4 (3.7) −0.6 (−0.9, −0.3) 0.37
Waist to hip ratio 0.93 (0.04) 0.93 (0.04) 0.93 (0.04) 0.93 (0.04) 0.92 (0.04)
−0.01 (−0.01, 0.00) 0.94 (0.05) 0.94 (0.05) 0.94 (0.05) 0.93 (0.05) 0.93 (0.05) −0.01 (−0.01, 0.00) 0.93
Systolic blood pressure, mm Hg 124.0 (15.1) 126.1 (15.7) 122.0 (14.3) 115.2 (14.8) 121.9 (16.6)
−8.8 (−11.0, −6.7) 124.8 (16.0) 126.3 (15.1) 124.6 (14.2) 116.9 (13.1) 124.7 (13.6) −7.9 (−10.2, −5.6) 0.55
Diastolic blood pressure, mm Hg 79.5 (11.5) 76.9 (11.2) 73.7 (10.9) 70.5 (9.5) 73.7 (11.2)
−9.0 (−10.7, −7.2) 81.3 (12.5) 77.8 (11.3) 75.5 (11.2) 73.7 (10.0) 75.6 (10.3) −7.5 (−9.3, −5.8) 0.26
Triglycerides, mg/dL 103.9 (54.9) 103.2 (61.3) 98.0 (53.5) 95.8 (54.5) 103.1 (51.8)
−8.1 (−18.2, 2.1) 113.1 (55.7) 119.0 (58.1) 118.5 (82.6) 110.9 (88.0) 110.4 (51.7) −2.2 (−20.0, 15.5) 0.57
Total cholesterol, mg/dL 209.9 (33.2) 208.6 (33.9) 209.4 (33.8) 200.2 (33.7) 208.3 (35.9)
−9.7 (−14.3, −5.0) 214.5 (30.0) 211.6 (31.3) 218.1 (32.9) 207.9 (31.7) 212.4 (32.2) −6.6 (−9.8, −3.4) 0.28
HDL-C, mg/dL 58.5 (13.9) 57.0 (13.3) 58.0 (13.9) 56.0 (12.8) 56.7 (13.1)
−2.5 (−3.7, −1.3) 56.2 (11.1) 54.7 (11.0) 56.0 (12.1) 54.9 (11.2) 55.3 (11.7) −1.2 (−2.6, 0.1) 0.17
LDL-C, mg/dL 127.4 (30.8) 127.3 (32.4) 126.0 (30.8) 119.9 (30.7) 126.1 (32.2)
−7.5 (−11.4, −3.6) 133.4 (27.2) 129.6 (27.1) 132.6 (28.3) 126.1 (25.9) 131.1 (28.4) −7.2 (−10.0, −4.5) 0.92
Fasting blood glucose, mg/dL 85.1 (6.2) 85.2 (8.0) 85.0 (7.0) 84.5 (7.7) 83.0 (6.6)
−0.6 (−1.7, 0.5) 85.2 (7.4) 86.3 (7.0) 86.3 (9.3) 84.1 (7.7) 83.6 (6.8) −1.1 (−2.4, 0.1) 0.53
Glycated hemoglobin A1c, % 5.47 (0.29) 5.51 (0.27) 5.45 (0.27) 5.44 (0.26) 5.47 (0.28) −0.03 (−0.07, 0.01) 5.46 (0.25) 5.49 (0.29) 5.47 (0.28) 5.43 (0.28) 5.42 (0.29) −0.03 (−0.06, 0.00) 0.92
Fasting insulin, mU/mL 5.4 (2.3) 5.4 (3.0) 6.7 (8.1) 5.4 (2.0) 6.2 (4.1) 0.0 (−0.5, 0.4) 5.8 (2.4) 5.9 (3.7) 7.1 (4.2) 5.8 (2.8) 6.5 (2.6) 0.1 (−0.5, 0.6) 0.81
HOMA-R 1.14 (0.50) 1.15 (0.68) 1.43 (1.85) 1.13 (0.45) 1.28 (0.91)
−0.01 (−0.12, 0.09) 1.22 (0.53) 1.27 (0.86) 1.53 (0.94) 1.23 (0.65) 1.34 (0.53) 0.01 (−0.12, 0.15) 0.76
Notes: Data at weeks 0, 4, 8, 12, and 16 are presented as mean (standard deviation). Changes from baseline to week 12 are presented as mean (95% confidence interval). 
P-value is a result of unpaired t-test for 12-week change between groups.
Abbreviations: HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; HOMA-R, homeostasis model assessment of insulin resistance; 
NA, not assessed.
difference between groups was found for the other primary 
and secondary outcomes. The daily total energy intake was 
decreased by 131 kcal in the A-mix group and by 77 kcal 
in the placebo group. The daily step count was increased by 
1,779 in the A-mix group and by 1,629 in the placebo group. 
No significant between-group differences were found in the 
consistency of the outcome measurements.
In the stratified analysis (Table 4) among the participants 
whose step counts increased by more than 1,000 steps during 
the 12-week intervention period, the A-mix group showed 
a significantly larger reduction in the abdominal total and 
subcutaneous fat areas compared with the placebo group 
(P=0.019 and 0.011, respectively). However, no significant 
between-group differences were observed in the participants 
whose step counts increased by fewer than 1,000 steps during 
the intervention.
In the safety assessment, no serious, unfavorable events 
occurred in the trial. A total of 133 nonserious unfavorable 
events were accounted for through participants’ diaries and 
medical interviews (Table S1). These occasions included 
fever, migraine, toothache, arthralgia, and common symp-
toms, for example, cold or sensitivity to dust. Although there 
were significant differences between the groups (e.g., allergy 
to pollen and allergic rhinitis), none of these were judged 
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study-related, adverse events were identified throughout the 
examination. Although common symptoms, such as cold 
or allergy to pollen, and some abnormal lab tests of blood 
biochemistry were identified, these unfavorable events were 
independent of group assignment or were judged by the 
study physician to be not related to the consumption of the 
test beverage.
The larger reduction in abdominal fat in the A-mix 
group could be explained by the following physiological 
 mechanisms described previously by our group.16 In brief, 
a previous study13 showed that pre-exercise ingestion of the 
A-mix was associated with increased blood concentrations 
of adrenaline and glucagon during and after exercise. Gan-
non and Nuttall reported that specific amino acids such as 
arginine, glycine, phenylalanine, and alanine can stimulate 
glucagon secretion.26 Therefore, the stimulation of gluca-
gon secretion by the A-mix is characteristic of these amino 
acids. In this way, the reduction in blood glucose by exer-
cise and a transient increase in blood amino acid levels by 
ingestion may stimulate pancreatic alpha cells and promote 
glucagon secretion. Additionally, past studies have noticed 
that some of the wide-ranging effects of adrenaline and 
glucagon appear to be facilitated by a common effector, 
cyclic adenosine 3′,5′-monophosphate.27 Therefore, cyclic 
adenosine 3′,5′-monophosphate-dependent lipolysis and 
fat oxidation appears to increase after a combination of the 
acute administration of A-mix and exercise, and the accumu-
lated effects reduced abdominal fat in this study. However, 
the pathway described above is one of the mechanisms for 
the enhanced lipolysis and fat oxidation associated with 
A-mix supplementation combined with exercise. Moreover, 
Table 2 Per-protocol-based analyses for primary and secondary outcomes (n=194)
Outcome A-mix group (n=95) Placebo group (n=99) P-value
Week 0 Week 4 Week 8 Week 12 Week 16 12-week change Week 0 Week 4 Week 8 Week 12 Week 16 12-week change
Primary outcomes
Abdominal total fat area, cm2 338.8 (73.6) NA NA 320.5 (76.1) NA
−18.3 (−25.8, −10.8) 326.2 (70.0) NA NA 317.8 (71.3) NA −8.3 (−14.5, −2.2) 0.041
Abdominal subcutaneous fat area, cm2 245.2 (66.1) NA NA 236.3 (68.1) NA
−8.9 (−14.5, −3.3) 228.3 (69.4) NA NA 226.8 (69.1) NA −1.5 (−6.2, 3.3) 0.047
Abdominal visceral fat area, cm2 93.6 (35.6) NA NA 84.1 (34.0) NA
−9.5 (−12.9, −6.0) 97.9 (39.0) NA NA 91.0 (38.8) NA −6.8 (−9.6, −4.1) 0.24
Secondary outcomes
Weight, kg 73.6 (8.9) 73.2 (8.7) 73.0 (8.8) 72.4 (8.7) 72.6 (8.8)
−1.2 (−1.7, −0.8) 73.5 (7.8) 73.1 (8.0) 72.9 (7.9) 72.3 (7.8) 72.4 (7.8) −1.2 (−1.7, −0.8) 0.96
Body mass index, kg/m2 27.1 (1.2) 27.0 (1.2) 26.9 (1.2) 26.7 (1.3) 26.7 (1.3)
−0.4 (−0.6, −0.3) 27.2 (1.3) 27.0 (1.4) 26.9 (1.5) 26.7 (1.5) 26.8 (1.6) −0.5 (−0.6, −0.3) 0.94
Percent fat mass, % 31.9 (7.0) 32.1 (7.4) 32.1 (7.4) 30.7 (7.5) 31.4 (7.7)
−1.2 (−1.6, −0.8) 31.8 (6.8) 32.2 (7.2) 32.0 (7.0) 30.6 (7.1) 31.3 (7.4) −1.2 (−1.6, −0.9) 0.93
Waist circumference, cm 94.0 (5.4) 93.8 (5.4) 93.0 (5.2) 92.6 (5.4) 92.3 (5.7)
−1.4 (−1.9, −0.9) 94.0 (5.4) 93.9 (5.4) 93.4 (5.4) 92.8 (5.5) 92.5 (5.5) −1.2 (−1.8, −0.7) 0.65
Hip circumference, cm 100.8 (4.3) 100.7 (4.0) 100.4 (4.0) 100.0 (4.1) 100.0 (4.2)
−0.8 (−1.2, −0.4) 100.2 (3.6) 100.1 (3.6) 99.8 (3.7) 99.6 (3.7) 99.4 (3.7) −0.6 (−0.9, −0.3) 0.37
Waist to hip ratio 0.93 (0.04) 0.93 (0.04) 0.93 (0.04) 0.93 (0.04) 0.92 (0.04)
−0.01 (−0.01, 0.00) 0.94 (0.05) 0.94 (0.05) 0.94 (0.05) 0.93 (0.05) 0.93 (0.05) −0.01 (−0.01, 0.00) 0.93
Systolic blood pressure, mm Hg 124.0 (15.1) 126.1 (15.7) 122.0 (14.3) 115.2 (14.8) 121.9 (16.6)
−8.8 (−11.0, −6.7) 124.8 (16.0) 126.3 (15.1) 124.6 (14.2) 116.9 (13.1) 124.7 (13.6) −7.9 (−10.2, −5.6) 0.55
Diastolic blood pressure, mm Hg 79.5 (11.5) 76.9 (11.2) 73.7 (10.9) 70.5 (9.5) 73.7 (11.2)
−9.0 (−10.7, −7.2) 81.3 (12.5) 77.8 (11.3) 75.5 (11.2) 73.7 (10.0) 75.6 (10.3) −7.5 (−9.3, −5.8) 0.26
Triglycerides, mg/dL 103.9 (54.9) 103.2 (61.3) 98.0 (53.5) 95.8 (54.5) 103.1 (51.8)
−8.1 (−18.2, 2.1) 113.1 (55.7) 119.0 (58.1) 118.5 (82.6) 110.9 (88.0) 110.4 (51.7) −2.2 (−20.0, 15.5) 0.57
Total cholesterol, mg/dL 209.9 (33.2) 208.6 (33.9) 209.4 (33.8) 200.2 (33.7) 208.3 (35.9)
−9.7 (−14.3, −5.0) 214.5 (30.0) 211.6 (31.3) 218.1 (32.9) 207.9 (31.7) 212.4 (32.2) −6.6 (−9.8, −3.4) 0.28
HDL-C, mg/dL 58.5 (13.9) 57.0 (13.3) 58.0 (13.9) 56.0 (12.8) 56.7 (13.1)
−2.5 (−3.7, −1.3) 56.2 (11.1) 54.7 (11.0) 56.0 (12.1) 54.9 (11.2) 55.3 (11.7) −1.2 (−2.6, 0.1) 0.17
LDL-C, mg/dL 127.4 (30.8) 127.3 (32.4) 126.0 (30.8) 119.9 (30.7) 126.1 (32.2)
−7.5 (−11.4, −3.6) 133.4 (27.2) 129.6 (27.1) 132.6 (28.3) 126.1 (25.9) 131.1 (28.4) −7.2 (−10.0, −4.5) 0.92
Fasting blood glucose, mg/dL 85.1 (6.2) 85.2 (8.0) 85.0 (7.0) 84.5 (7.7) 83.0 (6.6)
−0.6 (−1.7, 0.5) 85.2 (7.4) 86.3 (7.0) 86.3 (9.3) 84.1 (7.7) 83.6 (6.8) −1.1 (−2.4, 0.1) 0.53
Glycated hemoglobin A1c, % 5.47 (0.29) 5.51 (0.27) 5.45 (0.27) 5.44 (0.26) 5.47 (0.28) −0.03 (−0.07, 0.01) 5.46 (0.25) 5.49 (0.29) 5.47 (0.28) 5.43 (0.28) 5.42 (0.29) −0.03 (−0.06, 0.00) 0.92
Fasting insulin, mU/mL 5.4 (2.3) 5.4 (3.0) 6.7 (8.1) 5.4 (2.0) 6.2 (4.1) 0.0 (−0.5, 0.4) 5.8 (2.4) 5.9 (3.7) 7.1 (4.2) 5.8 (2.8) 6.5 (2.6) 0.1 (−0.5, 0.6) 0.81
HOMA-R 1.14 (0.50) 1.15 (0.68) 1.43 (1.85) 1.13 (0.45) 1.28 (0.91)
−0.01 (−0.12, 0.09) 1.22 (0.53) 1.27 (0.86) 1.53 (0.94) 1.23 (0.65) 1.34 (0.53) 0.01 (−0.12, 0.15) 0.76
Notes: Data at weeks 0, 4, 8, 12, and 16 are presented as mean (standard deviation). Changes from baseline to week 12 are presented as mean (95% confidence interval). 
P-value is a result of unpaired t-test for 12-week change between groups.
Abbreviations: HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; HOMA-R, homeostasis model assessment of insulin resistance; 
NA, not assessed.
Figure 2 Pattern of change in abdominal total fat area during 12-week intervention 
by treatment assignment (n=194).
Notes: Each data point represents the mean value for per-protocol-based analysis. 
Error bars indicate standard errors. 
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previous studies have suggested that glucagon secretion is 
regulated by gut hormones including glicentin, glucagon-like 
peptide-1, glucose-dependent insulinotropic polypeptide, 
and glucagon-like peptide-2 and other peptides secreted by 
the gastrointestinal tract, such as gastrin-releasing peptide, 
cholecystokinin, and secretin.28 Therefore, future studies are 
necessary to investigate the mechanism for the reduction in 
abdominal fat area observed with A-mix supplementation 
combined with physical activity promotion.
Although many trials have reported that the long-term 
supplementation of amino acids, combined with exercise, 
increased fat mobilization and/or weight loss,29–36 this study 
focused on the promotion of physical activity, rather than a 
specific exercise training program. For example, Lucotti et 
al focused on the effects of 8.3 g arginine supplementation 
combined with two 45 min sessions per day of whole body 
exercise five times per week for 5 weeks.33 Ispoglou et al 
focused on the effects of 4.0 g leucine supplementation 
combined with a resistance training program using eight 
standard exercise machines twice per week for 12 weeks.35 
These prescribed exercise programs were more intensive 
than that used in this study. Low-to-moderate intensity 
exercise may be better than vigorous exercise for the promo-
tion of fat mass reduction, because the substrate oxidation 
achieved during high-intensity exercise primarily involves 
carbohydrate oxidation.37 In addition, the encouragement of 
moderate-intensity exercise is more feasible and acceptable 
than that of high-intensity physical activity in patients with 
obesity. Therefore, the benefits of A-mix intake combined 
with mild physical activity can be applied to wider range of 
populations (eg older adults) than those with previous stud-
ies. Further studies are needed to address this hypothesis.
The safety of the A-mix has been demonstrated by a 
single-dose toxicity test, a 91-day repeated-dose toxicity 
test, and Ames test.38–40 In this trial, some adverse events 
were found. Generally, these symptoms frequently occur 
after beverage ingestion and exercise, particularly among 
previously inactive individuals. Hence, the A-mix dose used 
in this study is unlikely to cause a serious safety concern 
for long-term ingestion. Several reports confirm the amino 
acid imbalance between aromatic amino acids (tyrosine, 
phenylalanine, and tryptophan) and branched-chain amino 
acids (BCAAs: valine, leucine, isoleucine), which leads to 
a decreased Fischer’s ratio (BCAAs/aromatic amino acids) 
in both experimental models and clinical liver failure.41 
However, indicators of liver function, such as aspartate 
aminotransferase, alanine aminotransferase, and g-glutamyl 
transferase, were similar between the groups throughout the T
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study (Table S4). Therefore, it appears that the dose of 1,500 
mg/day of A-mix supplementation had no cross-talk effect 
on BCAA metabolism.
The trial conducted in this study has some important 
strengths. First, this trial had a double-blind, placebo-
controlled, and parallel-group randomized research design. 
Therefore, the findings are highly reliable. Second, the 
abdominal fat areas, as primary outcomes, were measured 
by CT, which is considered to provide the highest quality 
assessment of abdominal fat. Third, the study included 
the promotion of physical activity by approximately 1,000 
daily steps. This type of mild  intervention, as opposed to an 
entirely regulated exercise program, can be easily adopted 
by the general population.18,19 Finally, the retention rate of 
the study was almost perfect (99%).
There are also a few limitations of the study. First, we 
targeted overweight adults (25 kg/m2≤BMI<30 kg/m2). There-
fore, the effect of A-mix combined with physical activity 
promotion for obese adults (BMI≥30 kg/m2) was not inves-
tigated. Second, the changes in compliance outcomes, such 
as total and macronutrient intake, were different between the 
two groups; however, these between-group differences were 
not significant. Moreover, the energy intake of the test bever-
age is not included in this result. If it had been included, the 
difference of energy intake between the two groups would 
have been smaller.
Conclusion
The combination of A-mix supplementation and physical 
activity promotion facilitated abdominal fat reduction in 
overweight adults.
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Table 4 Stratified analyses: participants whose step counts increased by 1,000 steps or more (n=109) and increased by fewer than 
1,000 steps (n=83) during the 12-week intervention period
Week 0 Week 12 12-week change Week 0 Week 12 12-week change P-value
Participants whose step counts increased by more than 1,000 steps in 12 weeks
 A-mix group (n=61) Placebo group (n=48)  
Abdominal total fat area, cm2 330.1 (79.0) 304.6 (80.2)
−25.5 (−35.6, −15.4) 319.5 (69.4) 311.1 (69.8) −8.4 (−18.3, 1.4) 0.019
Abdominal subcutaneous fat 
area, cm2
231.3 (68.3) 217.7 (68.8)
−13.6 (−20.7, −6.5) 219.2 (68.7) 218.6 (67.9) −0.6 (−7.5, 6.3) 0.011
Abdominal visceral fat area, cm2 98.8 (37.1) 86.9 (34.2)
−11.9 (−16.7, −7.1) 100.3 (38.0) 92.5 (39.0) −7.8 (−12.5, −3.1) 0.23
Weight, kg 74.6 (9.0) 72.9 (8.7)
−1.7 (−2.3, −1.1) 74.0 (7.9) 72.5 (7.9) −1.4 (−2.0, −0.9) 0.51
Body mass index, kg/m2 27.0 (1.2) 26.4 (1.3)
−0.6 (−0.8, −0.4) 27.1 (1.3) 26.5 (1.5) −0.5 (−0.7, −0.3) 0.52
Percent fat mass, % 30.5 (6.9) 29.0 (7.5)
−1.5 (−2.1, −1.0) 31.3 (6.8) 29.9 (7.1) −1.4 (−1.9, −1.0) 0.77
Waist circumference, cm 93.9 (6.0) 92.1 (5.9)
−1.8 (−2.5, −1.1) 94.1 (5.1) 92.7 (5.1) −1.3 (−2.1, −0.6) 0.36
Hip circumference, cm 100.2 (4.7) 99.3 (4.2)
−0.9 (−1.4, −0.4) 99.8 (3.8) 99.2 (3.8) −0.6 (−1.0, −0.3) 0.42
Waist to hip ratio 0.94 (0.05) 0.93 (0.05)
−0.01 (−0.02, 0.00) 0.94 (0.04) 0.94 (0.04) −0.01 (−0.01, 0.00) 0.57
Participants whose step counts increased by fewer than 1,000 steps in 12 weeks
 A-mix group (n=34) Placebo group (n=49)  
Abdominal total fat area, cm2 354.4 (60.8) 348.9 (59.1)
−5.4 (−15.0, 4.1) 332.5 (71.8) 323.8 (74.3) −8.7 (−16.7, −0.7) 0.60
Abdominal subcutaneous fat 
area, cm2
270.1 (54.4) 269.7 (52.9)
−0.4 (−9.2, 8.4) 236.9 (71.1) 233.9 (71.4) −3.0 (−9.8, 3.9) 0.64
Abdominal visceral fat area, cm2 84.2 (30.9) 79.2 (33.6)
−5.1 (−9.4, −0.7) 95.6 (40.9) 89.9 (39.6) −5.7 (−9.1, −2.4) 0.80
Weight, kg 71.8 (8.7) 71.5 (8.9)
−0.3 (−0.9, 0.2) 72.7 (7.6) 71.7 (7.6) −1.0 (−1.6, −0.3) 0.17
Body mass index, kg/m2 27.3 (1.3) 27.1 (1.3)
−0.1 (−0.4, 0.1) 27.2 (1.4) 26.9 (1.5) −0.4 (−0.6, −0.1) 0.21
Percent fat mass, % 34.4 (6.6) 33.8 (6.6)
−0.6 (−1.0, −0.2) 32.3 (7.0) 31.2 (7.2) −1.0 (−1.6, −0.5) 0.24
Waist circumference, cm 94.0 (4.2) 93.4 (4.4)
−0.7 (−1.4, 0.0) 93.9 (5.8) 92.8 (6.0) −1.1 (−1.9, −0.3) 0.24
Hip circumference, cm 101.8 (3.4) 101.2 (3.4)
−0.6 (−1.1, −0.1) 100.4 (3.5) 99.9 (3.6) −0.5 (−1.0, 0.0) 0.78
Waist to hip ratio 0.92 (0.04) 0.92 (0.04) 0.00 (−0.01, 0.00) 0.94 (0.05) 0.93 (0.05) −0.01 (−0.01, 0.00) 0.25
Notes: Data at weeks 0 and 12 are presented as mean (standard deviation). Changes from baseline to week 12 are presented as mean (95% confidence interval). P-value is 
a result of unpaired t-test for 12-week change between groups.
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